Survey of Institutional Policies for Provision of “CMV-Safe” Blood in Ontario

Finlay, Laura; Nippak, Pria; Tiessen, James H.; Isaac, Winston; Callum, Jeannie; Cserti‐Gazdewich, Christine

doi:10.1093/ajcp/aqw181

Cited by 4 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be due to already optimised use of the CMV seronegative inventory or due to transfusion policy heterogeneity as was shown in the Canadian survey. 9 The slow uptake of new guidelines may indicate challenges in implementation such as time for staff education and facility policy rewriting, so it is possible that repeating the ordering audit at a later time point may have demonstrated more uptake. The present study aims to encourage further centres to adopt a single prevention strategy of LD only for the prevention of TT-CMV infection in HSCT.…”

Section: Discussionmentioning

confidence: 99%

“…7,8 Clinician surveys show that there continues to be heterogeneity in institution policies to prevent TT-CMV. 9 The heterogeneity is also demonstrated in Australia by CMV seronegative blood product ordering patterns. The present study is a retrospective audit of TT-CMV in two bone marrow transplant centres using 'double' (CMV seronegative and LD) versus 'single' (LD only) prevention strategies respectively to support the safety of a single approach in CMV negative recipient and donor allogeneic bone marrow transplant pairs and to determine whether there is added protection from a 'double' approach.…”

Section: Introductionmentioning

confidence: 98%

“…The ANZSBT guidelines are similar to the National Blood Authority recommendations and the Advisory committee on the Safety of Blood, Tissues and Organs guidelines 7,8 . Clinician surveys show that there continues to be heterogeneity in institution policies to prevent TT‐CMV 9 . The heterogeneity is also demonstrated in Australia by CMV seronegative blood product ordering patterns.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Centre‐based comparison of double versus single prevention strategy on transfusion‐transmitted cytomegalovirus in at‐risk haemopoietic stem cell transplant patients and a state survey on cytomegalovirus‐seronegative ordering practises

Zantomio

Bayly

Wong

et al. 2022

Internal Medicine Journal

View full text Add to dashboard Cite

Background: Universal leucocyte depletion reduces the risk of transfusion-transmitted cytomegalovirus; however, many clinicians still prescribe cytomegalovirus seronegative units.Aim: Our retrospective study aims to confirm the low risk of transfusion-transmitted cytomegalovirus with leucocyte depletion alone and demonstrate the ongoing variability in cytomegalovirus seronegative transfusion prescribing.Methods: Over a 9-year period (July 2009-July 2018), occurrences of transfusion transmitted cytomegalovirus in cytomegalovirus seronegative donor/recipient haemopoietic stem cell transplant pairs were compared at one allogeneic haemopoietic stem cell transplant centre providing cytomegalovirus seronegative blood products and leucocyte depletion (double prevention) versus another providing leucocyte depletion only (single prevention). Retrospective chart audit identified patient demographics, blood product exposure and cytomegalovirus infection by polymerase chain reaction. A separate audit examined cytomegalovirus seronegative blood product ordering in a broader range of hospital types. Results:We identified 122 and 66 cytomegalovirus-negative donor/recipient haemopoietic stem cell transplant pairs using double and single transfusion prevention strategy respectively. Transfusion exposure to red cells and pooled platelets was similar, although more apheresis platelets were used in the double prevention group. The cytomegalovirus infection rate was 3 (2.4%) and zero in the double and single prevention groups respectively. Cytomegalovirus seronegative unit ordering was not limited to hospitals with obstetric or neonatal populations, suggesting ongoing reliance of cytomegalovirus seronegative units outside this population. Conclusions:The analysis suggests a double prevention strategy does not provide additional protection against transfusion-transmitted cytomegalovirus. There is ongoing variability in the acceptance of leucocyte depletion alone despite the low risk of cytomegalovirus infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Centre‐based comparison of double versus single prevention strategy on transfusion‐transmitted cytomegalovirus in at‐risk haemopoietic stem cell transplant patients and a state survey on cytomegalovirus‐seronegative ordering practises

Zantomio

Bayly

Wong

et al. 2022

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…The results of a small survey (n ¼ 126 with 45% response rate) of Ontario hospital laboratories recently showed a similar lack of consensus regarding use of CMV-untested, leukoreduced versus CMV-seronegative, leukoreduced blood products. 30 This indicates a lack of institutional policy or guidelines, potentially due to the lack of evidence-based guidelines from national organizations. Additional data will be required to create such guidelines, ideally from prospective randomized clinical trials comparing the effectiveness of leukoreduced-only products versus CMV-seronegative and leukoreduced products in the prevention of CMV disease among high-risk patients.…”

Section: Discussionmentioning

confidence: 99%

Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation

Weisberg¹,

Staley²,

Williams³

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Cytomegalovirus (CMV) can be transmitted by cellular blood products, leading to severe disease in immunosuppressed patients such as neonates and transplant recipients. To mitigate transfusion-transmitted CMV (TT-CMV), “CMV-safe” blood products (leukoreduced and/or CMV-seronegative) are transfused. Attempts to develop practice guidelines for TT-CMV mitigation have been limited by paucity of high-quality clinical trials. Objective.— To assess current TT-CMV mitigation strategies across medical institutions for specific at-risk populations. Design.— Supplemental questions regarding TT-CMV and CMV disease mitigation were added to a College of American Pathologists Transfusion Medicine (Comprehensive) Participant Survey in 2015, addressing whether a given institution provided CMV-safe products for 6 at-risk patient populations. Results.— Ninety percent (2712 of 3032) of institutions reported providing universally leukoreduced blood products. Among institutions without universal leukoreduction, 92% (295 of 320) provided leukoreduced products on the basis of clinical criteria. Eighty-three percent (2481 of 3004) of respondents reported having availability of CMV-seronegative products; however, wide variation in policies was reported governing CMV-seronegative product use. Among all respondents, less than 5% reported using CMV prophylaxis and monitoring in high-risk patient groups. Transplant centers reported higher rates of CMV prophylaxis (25% [97 of 394] solid organ) and monitoring (15% [59 of 394] solid organ) for CMV-negative transplant recipients. Conclusions.— Universal leukoreduction is the primary strategy for mitigating TT-CMV. While most institutions have both CMV-seronegative and leukoreduced blood products available, consensus is lacking on which patients should receive these products. High-quality studies are needed to determine if CMV-seronegative and leukoreduced blood products are needed in high-risk patient populations.

show abstract

“…T2DM has reached pandemic proportions as over 400 million people are affected by diabetes [1]. T2DM is a major risk factor for the development of Alzheimer's disease (AD), and the hippocampus seems to be particularly vulnerable in T2DM [2–4].…”

Section: Introductionmentioning

confidence: 99%

Impaired Hippocampal Glutamate and Glutamine Metabolism in the db/db Mouse Model of Type 2 Diabetes Mellitus

et al. 2017

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is a risk factor for the development of Alzheimer's disease, and changes in brain energy metabolism have been suggested as a causative mechanism. The aim of this study was to investigate the cerebral metabolism of the important amino acids glutamate and glutamine in the db/db mouse model of T2DM. Glutamate and glutamine are both substrates for mitochondrial oxidation, and oxygen consumption was assessed in isolated brain mitochondria by Seahorse XFe96 analysis. In addition, acutely isolated cerebral cortical and hippocampal slices were incubated with [U-13C]glutamate and [U-13C]glutamine, and tissue extracts were analyzed by gas chromatography-mass spectrometry. The oxygen consumption rate using glutamate and glutamine as substrates was not different in isolated cerebral mitochondria of db/db mice compared to controls. Hippocampal slices of db/db mice exhibited significantly reduced 13C labeling in glutamate, glutamine, GABA, citrate, and aspartate from metabolism of [U-13C]glutamate. Additionally, reduced 13C labeling were observed in GABA, citrate, and aspartate from [U-13C]glutamine metabolism in hippocampal slices of db/db mice when compared to controls. None of these changes were observed in cerebral cortical slices. The results suggest specific hippocampal impairments in glutamate and glutamine metabolism, without affecting mitochondrial oxidation of these substrates, in the db/db mouse.

show abstract

Survey of Institutional Policies for Provision of “CMV-Safe” Blood in Ontario

Abstract: Standardization is lacking on practices to prevent TT-CMV. Although there are barriers to harmonizing practices, the apparent shift to policies acknowledging LR as a sufficient protection is likely to continue.

Cited by 4 publications

References 23 publications

Centre‐based comparison of double versus single prevention strategy on transfusion‐transmitted cytomegalovirus in at‐risk haemopoietic stem cell transplant patients and a state survey on cytomegalovirus‐seronegative ordering practises

Centre‐based comparison of double versus single prevention strategy on transfusion‐transmitted cytomegalovirus in at‐risk haemopoietic stem cell transplant patients and a state survey on cytomegalovirus‐seronegative ordering practises

Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation

Impaired Hippocampal Glutamate and Glutamine Metabolism in the db/db Mouse Model of Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About